Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label platform study of NIS793 combinations plus standard second-line therapy in metastatic colorectal cancer
MOH_2021-10-19_010240Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nisevokitug in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Novartis. Started Aug 2021; status: active, not recruiting.
02
Drugs
nisevokitug
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on MOH_2021-10-19_010240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-19_010240.